Pharmacogenetics goes genomic

被引：212

作者：

Goldstein, DB

Tate, SK

Sisodiya, SM

机构：

[1] UCL, Dept Biol, Galton Lab, London WC1E 6BT, England

[2] UCL, Inst Neurol, Dept Clin & Expt Epilepsy, London WC1N 3BG, England

来源：

NATURE REVIEWS GENETICS | 2003年 / 4卷 / 12期

关键词：

D O I：

10.1038/nrg1229

中图分类号：

Q3 [遗传学];

学科分类号：

071007 ; 090102 ;

摘要：

Most people in the developed world will sooner or later be given prescription drugs to treat common diseases or to reduce the risk of getting them. Almost everyone who takes medicines will, at some stage, encounter those that do not work as well as they do in other people or even that cause an adverse reaction. Pharmacogenetics seeks to reduce the variation in how people respond to medicines by tailoring therapy to individual genetic make-up. It seems increasingly likely that investment in this field might be the most effective strategy for rapidly delivering the public health benefits that are promised by the Human Genome Project and related endeavours.

引用

收藏

页码：937 / 947

页数：11

相关论文

共 55 条

[1] Discovering genotypes underlying human phenotypes: past successes for mendelian disease, future approaches for complex disease [J].

Botstein, D ;

Risch, N .

NATURE GENETICS, 2003, 33 (Suppl 3) :228-237

[2] THE RESPONSE TO LOVASTATIN TREATMENT IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IS MODULATED BY APOLIPOPROTEIN-E POLYMORPHISM [J].

CARMENA, R ;

ROEDERER, G ;

MAILLOUX, H ;

LUSSIERCACAN, S ;

DAVIGNON, J .

METABOLISM-CLINICAL AND EXPERIMENTAL, 1993, 42 (07) :895-901

[3] GENE DOSE OF APOLIPOPROTEIN-E TYPE-4 ALLELE AND THE RISK OF ALZHEIMERS-DISEASE IN LATE-ONSET FAMILIES [J].

CORDER, EH ;

SAUNDERS, AM ;

STRITTMATTER, WJ ;

SCHMECHEL, DE ;

GASKELL, PC ;

SMALL, GW ;

ROSES, AD ;

HAINES, JL ;

PERICAKVANCE, MA .

SCIENCE, 1993, 261 (5123) :921-923

[4] High-resolution haplotype structure in the human genome [J].

Daly, MJ ;

Rioux, JD ;

Schaffner, SE ;

Hudson, TJ ;

Lander, ES .

NATURE GENETICS, 2001, 29 (02) :229-232

[5] RESEARCH-AND-DEVELOPMENT COSTS FOR NEW DRUGS BY THERAPEUTIC CATEGORY - A STUDY OF THE UNITED-STATES PHARMACEUTICAL-INDUSTRY [J].

DIMASI, JA ;

HANSEN, RW ;

GRABOWSKI, HG ;

LASAGNA, L .

PHARMACOECONOMICS, 1995, 7 (02) :152-169

[6] The price of innovation: new estimates of drug development costs [J].

DiMasi, JA ;

Hansen, RW ;

Grabowski, HG .

JOURNAL OF HEALTH ECONOMICS, 2003, 22 (02) :151-185

[7] COST OF INNOVATION IN THE PHARMACEUTICAL-INDUSTRY [J].

DIMASI, JA ;

HANSEN, RW ;

GRABOWSKI, HG ;

LASAGNA, L .

JOURNAL OF HEALTH ECONOMICS, 1991, 10 (02) :107-142

[8] The effect of common polymorphisms of the β2-adrenergic receptor on agonist-mediated vascular desensitization [J].

Dishy, V ;

Sofowora, GG ;

Xie, HG ;

Kim, RB ;

Byrne, DW ;

Stein, CM ;

Wood, AJJ .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (14) :1030-1035

[9] Complex promoter and coding region β2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness [J].

Drysdale, CM ;

McGraw, DW ;

Stack, CB ;

Stephens, JC ;

Judson, RS ;

Nandabalan, K ;

Arnold, K ;

Ruano, G ;

Liggett, SB .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (19) :10483-10488

[10]

El-Bacha RS, 1999, CELL MOL BIOL, V45, P15

← 1 2 3 4 5 6 →